Premium
Allergen Challenge Increases Anandamide in Bronchoalveolar Fluid of Patients With Allergic Asthma
Author(s) -
Zoerner A A,
Stichtenoth D O,
Engeli S,
Batkai S,
Winkler C,
Schaumann F,
Janke J,
Holz O,
Krug N,
Tsikas D,
Jordan J,
Hohlfeld J M
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.94
Subject(s) - anandamide , bronchoalveolar lavage , medicine , asthma , endocannabinoid system , allergen , immunology , allergy , inflammation , airway , cannabinoid , lung , anesthesia , cannabinoid receptor , receptor , agonist
Preclinical studies suggest that the endocannabinoid anandamide restrains allergic airway obstruction and inflammation. Therefore, we applied saline or allergens via bronchoscopy into different lung segments of patients with allergic asthma. Twenty‐four hours later, anandamide concentrations in bronchoalveolar lavage fluids had increased more than fourfold. Anandamide concentrations correlated with severity of airway inflammation. These observations suggest that allergen exposure specifically activates the pulmonary endocannabinoid system (ECS) in patients with allergic asthma. Clinical Pharmacology & Therapeutics (2011) 90 3, 388–391. doi: 10.1038/clpt.2011.94